or Try an Advanced Search...

    Disorders Stocks List

    Symbol Grade Name % Change
    CORT B Corcept Therapeutics Incorporated -3.33
    ELYM B Eliem Therapeutics, Inc 0.65
    LFST B LifeStance Health Group, Inc. 0.00
    ELDN C Eledon Pharmaceuticals, Inc. 6.59
    IGC C India Globalization Capital Inc. -2.60
    DXR C Daxor Corporation -3.10
    REGN C Regeneron Pharmaceuticals, Inc. 1.06
    CPRX C Catalyst Pharmaceutical Partners, Inc. 0.37
    CGTX C Cognition Therapeutics, Inc. -1.02
    IBIO C iBio, Inc. 6.73
    View As Page of Charts
    Related Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Specialty & Generic Medical Care Facilities Medical Instruments & Supplies
    Related Stock Lists: Medicine Biopharmaceutical Biotechnology Epilepsy Pain Pharmaceutical Psychiatric Diagnosis Alzheimer's Disease Clinical Research Depression Geriatrics Health Sciences Medication Parkinson's Disease Abnormal Psychology Aging Associated Diseases Anemia Angioedema Angiogenesis Anthrax

    Related ETFs - A few ETFs which own one or more of the above listed Disorders stocks.

    Symbol Grade Name Weight
    FBT D First Trust Amex Biotech Index Fund 10.63
    PJP A PowerShares Dynamic Pharmaceuticals 10.45
    IBB C iShares Nasdaq Biotechnology Index Fund 8.34
    IBBQ B Invesco Nasdaq Biotechnology ETF 8.33
    PBE C PowerShares Dynamic Biotech & Genome 8.33
    View all Disorders ETFs...
    Compare ETFs
    Compare FBT to IBB Compare IBB to IBBQ Compare IBB to PBE

        Disorders Stocks Recent News

        Date Stock Title
        May 31 CORT Corcept (CORT) Up 24.5% Since Last Earnings Report: Can It Continue?
        May 31 REGN FDA Extends Review Deadline For Regeneron/Sanofi's Dupixent For 'Smoker's Lungs' Disease
        May 31 REGN FDA Delays Decision on Sanofi (SNY)-Regeneron Dupixent in COPD
        May 31 REGN Regeneron/ Sanofi say FDA has delayed Dupixent COPD label
        May 31 CORT Insider Sale: Chief Development Officer William Guyer Sells 30,000 Shares of Corcept ...
        May 31 REGN Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
        May 31 REGN Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation
        May 30 CPRX Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE®
        May 30 REGN Biohaven doses first subject in Phase I/II tumour treatment study
        May 29 CORT Corcept (CORT) Rises as Cushing's Syndrome Study Meets Goal
        May 29 REGN Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors
        May 28 IGC IGC Pharma Announces Patient Enrollment at Neurostudies in Phase 2 Trial Investigating IGC-AD1
        May 28 CORT Corcept climbs as late-stage trial for Cushing’s syndrome therapy succeeds
        May 28 CPRX Catalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024
        May 28 CORT Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing’s Syndrome)
        May 27 REGN The Biggest Biotechnology Company in Europe
        Related Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Specialty & Generic Medical Care Facilities Medical Instruments & Supplies
        Related Stock Lists: Medicine Biopharmaceutical Biotechnology Epilepsy Pain Pharmaceutical Psychiatric Diagnosis Alzheimer's Disease Clinical Research Depression Geriatrics Health Sciences Medication Parkinson's Disease Abnormal Psychology Aging Associated Diseases Anemia Angioedema Angiogenesis Anthrax
        Disorders

        Disorder may refer to randomness, non-order, or no intelligible pattern. Disorder may also refer to:

        More about Disorders
        Browse All Tags